Search - Role of intra-Clonal HEterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias Access content directly

Filter your results

40 Results
Deposit type : Notice

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

Meletios Dimopoulos , Judith Trotman , Alessandra Tedeschi , Jeffrey V Ma , David Ma et al.
Lancet Oncology, 2017, 18 (2), pp.241 - 250. ⟨10.1016/S1470-2045(16)30632-5⟩
Journal articles hal-01653571v1

Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients

Loic Ysebaert , Thérèse Aurran-Schleinitz , Caroline Dartigeas , Marie-Sarah Dilhuydy , Pierre Feugier et al.
American Journal of Hematology, 2017, 92 (8), pp.E166 - E168. ⟨10.1002/ajh.24773⟩
Journal articles hal-01655976v1

Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia families

Anne Laure Renault , Noura Mebirouk , Eve Cavaciuti , Dorothée Le Gal , J. Lecarpentier et al.
Carcinogenesis, 2017, 38 (10), pp.994-1003. ⟨10.1093/carcin/bgx074⟩
Journal articles hal-01658591v1

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma

Steven Le Gouill , Catherine Thieblemont , Lucie Oberic , Anne Moreau , Krimo Bouabdallah et al.
New England Journal of Medicine, 2017, 377 (13), pp.1250-1260. ⟨10.1056/NEJMoa1701769⟩
Journal articles hal-02329536v1

Aggressive skin cancers in patients who experienced chronic GvHD after allogeneic bone marrow transplantation

A Zampaolo , J. Kanold , O. Tournilhac , F Franck , M Bachelerie et al.
Bone Marrow Transplantation, 2017, 52 (1), pp.130 - 131. ⟨10.1038/bmt.2016.187⟩
Journal articles hal-01655888v1

Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia

Yannick Le Bris , Stéphanie Struski , Romain Guiéze , Caroline Rouvellat , Nais Prade et al.
Hematological Oncology, 2017, 35 (4), pp.664 - 670. ⟨10.1002/hon.2349⟩
Journal articles hal-01677945v1

A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments

Jerome Stirnemann , Nadia Belmatoug , Fabrice Camou , Christine Serratrice , Roseline Rose et al.
International Journal of Molecular Sciences, 2017, 18 (2), pp.441. ⟨10.3390/ijms18020441⟩
Journal articles hal-01653579v1

Étude du chimérisme après allogreffe de cellules hématopoïétiques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Valérie Dubois , Mehdi Alizadeh , Jean Henri Bourhis , Pascaline Etancelin , Olivier Farchi et al.
Bulletin du Cancer, 2017, 104 (12), pp.S59 - S64. ⟨10.1016/j.bulcan.2017.08.010⟩
Journal articles hal-01664161v1

Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study

Sotheara Moeung , Christine Chevreau , Sophie Broutin , Jérome Guitton , Bénédicte Lelièvre et al.
Clinical Cancer Research, 2017, 23 (23), pp.7171 - 7179. ⟨10.1158/1078-0432.CCR-17-1344⟩
Journal articles hal-01659726v1

Reduced-­intensity vs reduced­-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non­Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

A. Le Bourgeois , M. Labopin , D. Blaise , P. Ceballos , S. Vigouroux et al.
Annals of Oncology, 2017, 28 (9), pp.2191-2198. ⟨10.1093/annonc/mdx274⟩
Journal articles hal-01655965v1

Effect of Azithromycin on Airflow Decline–Free Survival After Allogeneic Hematopoietic Stem Cell Transplant

Anne Bergeron , Sylvie Chevret , Angela Granata , Patrice Chevallier , Laure Vincent et al.
JAMA Ophthalmology, 2017, 318 (6), pp.557-566. ⟨10.1001/jama.2017.9938⟩
Journal articles hal-01655930v1

Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial

Francoise Kraeber-Bodere , Amandine Pallardy , Hervé Maisonneuve , Loïc Campion , Anne Moreau et al.
The Lancet Haematology, 2017, 4 (1), pp.e35-e45. ⟨10.1016/S2352-3026(16)30168-5⟩
Journal articles hal-02425339v1

Plasma chitotriosidase activity versus CCL18 level for assessing type I Gaucher disease severity: protocol for a systematic review with meta-analysis of individual participant data

Tatiana Raskovalova , Patrick B. Deegan , Ruby Yang , Elena Pavlova , Jérôme Stirnemann et al.
Systematic Reviews, 2017, 6 (1), pp.87. ⟨10.1186/s13643-017-0483-x⟩
Journal articles hal-01655857v1

Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group

Sophie Michallet , Arnaud Campidelli , Helene Lequeu , Marie-Sarah Dilhuydy , Olivier Tournilhac et al.
American Journal of Hematology, 2017, 92 (6), pp.E105 - E107. ⟨10.1002/ajh.24715⟩
Journal articles hal-01653723v1

Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study

Alexandre Morel , Josette Brière , Laurence Lamant , Michael Loschi , Corinne Haioun et al.
European Journal of Cancer, 2017, 83, pp.146 - 153. ⟨10.1016/j.ejca.2017.06.026⟩
Journal articles hal-01655967v1

A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone

Véronique Leblond , Pierre Morel , Marie-Sarah Dilhuidy , Xavier Leleu , Carole Soussain et al.
Leukemia & lymphoma, 2017, 58 (11), pp.2615 - 2623. ⟨10.1080/10428194.2017.1307357⟩
Journal articles hal-01655961v1

SnapShot: Chronic Lymphocytic Leukemia

Elisa ten Hacken , Romain Guièze , Catherine J. Wu
Cancer Cell, 2017, 32 (5), pp.716 - 716.e1. ⟨10.1016/j.ccell.2017.10.015⟩
Journal articles hal-01659737v1

A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD

Gérard Socié , Stéphane Vigouroux , Ibrahim Yakoub-Agha , Jacques-Olivier Bay , Sabine Furst et al.
Blood, 2017, 129 (5), pp.643 - 649. ⟨10.1182/blood-2016-09-738625⟩
Journal articles hal-01655868v1

Santé publique et volonté politique : convergences et divergences

Stéphane Vignot , Gilles L’allemain , Jacques-Olivier Bay
Bulletin du Cancer, 2017, 104 (7-8), pp.597 - 598. ⟨10.1016/j.bulcan.2017.06.007⟩
Journal articles hal-01655997v1

Retour vers le futur

Stéphane Vignot , Gilles L’allemain , Jacques-Olivier Bay
Bulletin du Cancer, 2017, 104 (9), pp.701 - 702. ⟨10.1016/j.bulcan.2017.08.001⟩
Journal articles hal-01655998v1

Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party

B Bento , B Boumendil , F Finel , S. Le Gouill , S Amorim et al.
Bone Marrow Transplantation, 2017, 52 (8), pp.1120 - 1125. ⟨10.1038/bmt.2017.88⟩
Journal articles hal-01655912v1

Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study

Pernelle Noize , Angela Grelaud , Jacques-Olivier Bay , Christine Chevreau , Marine Gross-Goupil et al.
Pharmacoepidemiology and Drug Safety, 2017, 26 (2), pp.1561-1569. ⟨10.1002/pds.4228⟩
Journal articles hal-01659732v1

Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the société Francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Laurent Gilardin , Sandrine Delignat , Ivan Peyron , Mathieu Ing , Yu-Chun Lone et al.
Bone Marrow Transplantation, 2017, 52 (5), pp.678-682. ⟨10.1038/bmt.2016.360⟩
Journal articles hal-02466291v1

Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)

Loïc Lebellec , Bruno Chauffert , Jean-Yves Blay , Axel Le Cesne , Christine Chevreau et al.
European Journal of Cancer, 2017, 79, pp.119 - 128. ⟨10.1016/j.ejca.2017.03.037⟩
Journal articles hal-01655981v1

Pomalidomide dans les myélomes multiples

Aurore Dougé , Richard Lemal , Carine Chaleteix
Bulletin du Cancer, 2017, 104 (9), pp.707 - 713. ⟨10.1016/j.bulcan.2017.04.005⟩
Journal articles hal-01655995v1

Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia

Gregory Lazarian , Romain Guieze , Catherine J. Wu
Journal of Clinical Oncology, 2017, 35 (9), pp.984 - 993. ⟨10.1200/JCO.2016.71.0822⟩
Journal articles hal-01655956v1

Bone marrow hematons: An access point to the human hematopoietic niche

Alexandre Janel , Juliette Berger , Céline Bourgne , Richard Lemal , Nathalie Boiret-Dupré et al.
American Journal of Hematology, 2017, 92 (10), pp.1020 - 1031. ⟨10.1002/ajh.24830⟩
Journal articles hal-01655946v1

First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study

Godelieve Meunier , Loic Ysebaert , Phi Linh Nguyen-Thi , Stéphane Leprêtre , Anne Quinquenel et al.
Hematological Oncology, 2017, 35 (4), pp.671 - 678. ⟨10.1002/hon.2370⟩
Journal articles hal-01672884v1

Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia

Caroline Algrin , Jean-Louis Golmard , Mauricette Michallet , Oumedaly Reman , Anne Huynh et al.
European Journal of Haematology, 2017, 98 (4), pp.363 - 370. ⟨10.1111/ejh.12836⟩
Journal articles hal-01653556v1

Type 3 Gaucher disease, diagnostic in adulthood

Charles Detollenaere , Monia Benghergbia , Anaïs Brassier , Thierry Billette de Villemeur , Daniel Amsallem et al.
Molecular Genetics and Metabolism Reports, 2017, 13, pp.1 - 2. ⟨10.1016/j.ymgmr.2017.07.002⟩
Journal articles hal-01653712v1